专利号:US-10793557-B2 优先权日:2018-04-03 标题 :Sting agonist compounds 发明人:ALTMAN MICHAEL D; CASH BRANDON D; CHILDERS MATTHEW LLOYD; CUMMING JARED N; DEMONG DUANE E; HAIDLE ANDREW MARC; HENDERSON TIMOTHY J; JEWELL JAMES P; LARSEN MATTHEW A; LIM JONGWON; LU MIN; OTTE RYAN D; TROTTER BENJAMIN WESLEY 权利人:MERCK SHARP & DOHME 摘要:Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
专利号:US-2024400861-A1 优先权日:2021-10-01 标题 :Triazole- And/Or Triazolium-Based Polymers And Copolymers As Additives For Chemical Mechanical Planarization Slurries 发明人:LARBIG GREGOR; KIRSCH PEER; HENGST MATTHIAS; SHI XIAOBO; STENDER MATTHIAS 权利人:VERSUM MAT US LLC 摘要:Synthesis of triazole- and/or triazolium-based polymers is disclosed. Chemical Mechanical Planarization (CMP) slurries comprise abrasives; activator; oxidizing agent; additive comprising triazole- and/or triazolium-based polymers; and water. The use of the synthesized triazole- and/or triazolium-based polymers in the CMP slurries reduces dishing and erosion in highly selective tungsten slurries.
专利号:US-11702430-B2 优先权日:2018-04-03 标 题:Aza-benzothiophene compounds as STING agonists 发明人:ALTMAN MICHAEL D; CASH BRANDON D; CUMMING JARED N; DEMONG DUANE E; HAIDLE ANDREW M; JEWELL JAMES P; LARSEN MATTHEW A; LU MIN; OTTE RYAN D; TAOKA BRANDON M; TROTTER BENJAMIN WESLEY; TRUONG QUANG T 权利人:MERCK SHARP & DOHME LLC; ALTMAN MICHAEL D; CASH BRANDON D; CUMMING JARED N; DEMONG DUANE E; HAIDLE ANDREW M; JEWELL JAMES P; LARSEN MATTHEW A; LU MIN; OTTE RYAN D; TAOKA BRANDON M; TROTTER BENJAMIN WESLEY; TRUONG QUANG T 摘要:Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 , R 5 , R 6 , R 8 , R 9 , A, X 1 , X 2 , and X 3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
专利号:WO-2024073211-A1 优先权日:2022-09-29 标题:Guanidinium-based polyionic liquids and their use as additives for chemical mechanical planarization slurries 发明人:LARBIG GREGOR; KIRSCH PEER; SHI XIAOBO 权利人:VERSUM MAT US LLC 摘要:Synthesis of guanidinium-based polymers is disclosed. Chemical Mechanical Planarization (CMP) slurries comprise abrasives; activator; oxidizing agent; additive comprising guanidinium-based polymers; and water. The use of the synthesized guanidinium-based polymers in the CMP slurries reduces dishing and erosion in highly selective tungsten slurries.
专利号:US-2025215130-A1 优先权日:2022-04-11 标 题:Polycationic Polymer Or Copolymer Having Different Cation Types For Slurries In Chemical Mechanical Planarization 发明人:LARBIG GREGOR; SHI XIAOBO 权利人:MERCK PATENT GMBH; VERSUM MAT US LLC 摘要:Synthesis of polycationic polymer or copolymer is disclosed. The polycationic polymer or copolymer are formed by at least one first cationic monomer and at least one second cationic monomer wherein the first cationic monomer and the second cationic monomer have different cationic groups; such as imidazolium group and non-imidazolium group. Chemical Mechanical Planarization (CMP) slurries comprise abrasives; activator; oxidizing agent; additive comprising polycationic polymer or copolymer; and water are also disclosed. The use of the synthesized polycationic polymer or copolymer in the CMP slurries reduces dishing and erosion in highly selective tungsten slurries.
专利号:WO-2024073209-A1 优先权日:2022-09-30 标 题 :Modified water-soluble polysaccharides having different cation types for slurries in chemical mechanical planarization 发明人:DAVIDI INBAL; LARBIG GREGOR; SHI XIAOBO; MA SANA 权利人:VERSUM MAT US LLC 摘要:Synthesis of cationic-modified water-soluble polysaccharide is disclosed. The cation is pendent to the polysaccharide backbone. Chemical Mechanical Planarization (CMP) slurries comprise abrasives; activator; oxidizing agent; additive comprising cationic-modified water-soluble polysaccharide; and water. The use of the synthesized cationic-modified water-soluble polysaccharide in the CMP slurries reduces dishing and erosion in highly selective tungsten slurries.
1: Diaz-Padilla I, Siu LL. Brivanib alaninate for cancer. Expert Opin Investig Drugs. 2011 Apr;20(4):577-86. doi: 10.1517/13543784.2011.565329. Epub 2011 Mar 11. 8(9):1083-90. doi: 10.2217/fon.12.104. 170:105721. doi: 10.1016/j.phrs.2021.105721. Epub 2021 Jun 8. 30(11):4477-83. 235(2):1259-1273. doi: 10.1002/jcp.29041. Epub 2019 Jul 4. 31(28):3483-6. doi: 10.1200/JCO.2013.49.7941. Epub 2013 Aug 26. 120(6):601-611. doi: 10.1038/s41416-018-0375-4. Epub 2019 Feb 15. 8: Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Küpper JH, Chen S, Guo L, Ceckova M, Staud F. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Mol Pharm. 2019 Nov 4;16(11):4436-4450. doi: 10.1021/acs.molpharmaceut.9b00361. Epub 2019 Oct 21. 31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. 9(4):e92273. doi: 10.1371/journal.pone.0092273. Erratum in: PLoS One. 2015;10(11):e0142355.
合成参考文献
参考文献:10.1007/s10549-009-0677-6 摘要:Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Research and Treatment. 2009 Dec 19;123(3):747–55. doi: 10.1007/s10549-009-0677-6. 摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749